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Chugai, the Japanese subsidiary of Roche, is developing a
humanized anti-interleukin (IL)-6 receptor monoclonal antibody
MRA for the potential treatment of multiple myeloma, rheumatoid
arthritis, Crohn's disease and other IL-6-related disorders. MRA is
currently undergoing phase II clinical trials for these indications.
Introduction
Interleukin (IL)-6 is a pleiotropic cytokine with a wide range
of biological activities, including regulation of immune
responses, support of hematopoiesis and generation of
acute-phase reactions [475335]. Deregulation of IL-6
production has been implicated in the pathogenesis of a
variety of diseases. Chronic inflammation of the joint in
rheumatoid arthritis (RA) induces IL-6 production by
synovial cells, macrophages and lymphocytes in the affected
synovium. Overproduction of IL-6 appears to be involved in
the pathogenesis of pannus formation, angiogenesis,
infiltration of mononuclear cells and destruction of cartilage
and bone [475335], [475553], [475555]. IL-6 is also present at
very high levels in the serum and/or related tissue from
patients with Crohn's disease (CD) [475336], Castleman's
disease [475337], multiple myeloma (MM) [475338] and
systemic lupus erythematosus (SLE) [475341]; it may,
therefore, play a crucial role in the pathogenesis of these
diseases. As a result, therapy involving blockade of IL-6
functions may constitute a new therapeutic strategy.
The functions of IL-6 are mediated through a receptor
system comprising two cell-surface molecules, a signal
transducer and a binding molecule (the IL-6 receptor, IL-6R).
Blockade of IL-6 binding to its receptor seems to be specific
and effectively inhibits IL-6 functions. Chugai is therefore
developing MRA, a humanized anti-IL-6R monoclonal
antibody for potential use in the treatment of IL-6-related
disorders, including RA, CD and Castleman's disease
[459399], [466916], [469932].
Synthesis and SAR
PM-1, a mouse monoclonal antibody against human
recombinant IL-6R, was generated from a mouse immunized
with IL-6R partially purified from the human myeloma cell
line U266 [475342]. In humans, the production of
neutralizing antibodies to mouse antibodies can be clinically
problematic, and cause the effects of administered
antibodies to be transient [154800]. To prevent the induction
of such antibodies against the anti-IL-6R antibody, the PM-1
antibody was reshaped to create MRA [154800].
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Action IL-6 antagonist, Immunosuppressant
Indication Arthritis, Autoimmune disease, Castleman's
disease, Crohn's disease, Myeloproliferative disorder,
Rheumatoid arthritis, Systemic lupus erythematosus
Biotechnology Humanized monoclonal antibody
Synonyms Anti-interleukin-6 receptor mAb, hPM-1, IL-6
receptor MAb
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Complementarity-determining regions of the mouse PM-1
light and heavy chain variable regions were grafted to
human REI and NEW framework regions (FRs),
respectively. Template DNA was prepared using NcoI-
BamHI fragments containing DNA sequences coding for the
reshaped human light and heavy chain variable regions,
which have FRs from human REI and NEW, respectively.
These were then subcloned into the HindIII-BamHI site of
pUC19 vector using a HindIII-NcoI adaptor. Using
appropriate mutagenic PCR primers and template DNA,
several versions were constructed. After DNA sequencing,
the HindIII-BamHI fragments coding for reshaped human
PM-1 variable regions were excised from pUC19 vectors and
inserted in the HindIII-BamHI sites in human elongation
factor expression vectors. Plasmid DNAs were transfected
into COS cells for production of MRA and this antibody was
purified. The ability to bind to IL-6R and the inhibitory
effect of IL-6 function of the original PM-1 were conserved
in the MRA molecule [154800]. Thus, the administration of
MRA induces hardly any anti-MRA antibodies and it can be
repeatedly administered [154800].
Pharmacology
In vitro and in vivo data have shown that MRA blocks IL-6
functions in the cynomolgus monkey. MRA inhibited two
functional parameters in vitro in this animal; T-cell
proliferation stimulated by phytohemaglutinin and human
IL-6, and IgG production evoked by Staphylococcus aureus
Cowan-1- and human IL-6-stimulated B-lymphocytes
[472428]. MRA (5 mg/kg iv) completely inhibited IL-6-
induced typical responses (such as elevation of blood
platelet counts and serum C-reactive protein (CRP) levels) in
cynomolgus monkeys [472418], [472427].
The in vivo effect of MRA on the development of collagen-
induced arthritis was examined in cynomolgus monkeys.
MRA (10 mg/kg iv) given once weekly for 13 weeks
significantly inhibited arthritis symptoms. The elevation of
serum CRP and fibrinogen levels was also inhibited, as was
erythrocyte sedimentation rate (ESR). Furthermore,
radiographic and histological examination showed that MRA
treatment suppressed joint destruction [472418]. In severe
combined immunodeficiency (SCID) mice in which human RA
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synovial tissue was grafted, MRA (100 µg ip) administered
once weekly for 4 weeks significantly decreased the number of
inflammatory cells and metalloprotease-positive cells in the
implanted tissues [475344]. These results suggest that MRA
may be an attractive agent for the treatment of RA.
In SCID mice subcutaneously inoculated with solid tumors of
the S6B45 myeloma cell line, PM-1 (100 µg ip) administered 24
h after tumor inoculation, with ten subsequent injections at 48
h intervals, strongly inhibited the growth of myeloma cells
[248634]. MRA (2 mg as a single iv injection administered on
the day after tumor transplantation) substantially suppressed
the elevation of serum M-protein and development of tumor-
associated abnormalities, and significantly increased the
lifespan in a SCID mouse xenograft MM model induced by iv
injection of the human MM cell line KPMM2 [475345]. These
in vivo results suggest that MRA may be effective in the
treatment of MM.
Further preclinical studies suggest a therapeutic potential of
MRA in the treatment of human SLE and CD. MR16-1, a rat
anti-mouse IL-6R antibody, potently suppressed the
development of autoimmune disease in BWF1 mice, as a
model of human SLE, and this was attributed to its effect on
the specific suppression of IgG class antibody production
[475341]. In the murine colitis model induced by transfer of
CD45Rbhigh CD4+ T-cells from BALB/c mice, ip injection of
rat anti-murine IL-6R antibody (2 mg at the time of colitis
induction and 1 mg weekly for up to 8 weeks) significantly
inhibited the average colitis score. T-cell expansion in
treated mice was less remarkable than in the control mice
and expression of the adhesion molecules ICAM-2 and
VCAM-1 were inhibited [475336].
Metabolism
To investigate the kinetic properties of MRA, cynomolgus
monkeys were administered MRA (4 or 40 mg/kg iv) once
weekly for 13 weeks. Serum MRA concentrations showed
linearity between the two doses. When the first doses of 4
and 40 mg/kg were infused into two monkeys, for each
dose, serum concentrations of MRA reached maximum
levels of 93 and 138 µg/ml for the 4 mg/kg dose and 762
and 1116 µg/ml for the 40 mg/kg dose immediately after
administration. The MRA concentrations rapidly declined
during the first 24 h and then decreased slowly. The levels of
MRA 1 week after dosing were 37 and 49 µg/ml, and 461
and 528 µg/ml, respectively. Similar changes in MRA serum
concentrations were also observed at 2, 4, 8 and 12 weeks.
Concentrations of MRA in bone marrow were almost equal
to those in serum [472429]. Serum concentrations of MRA
were maintained for a long period; in some cases, there was
a sufficient level of MRA to inhibit IL-6 functions 1 week
after administration [472427].
Toxicity
In order to investigate the toxicological properties of MRA,
cynomolgus monkeys were administered MRA (0, 4 or 40
mg/kg iv) once weekly for 13 weeks. During the period of
treatment, no changes in clinical signs or symptoms of
anaphylaxis were observed. Food consumption of each
monkey was normal and there were no differences in body
weight between control and treated animals. Hematological
and biochemical parameters, including blood platelet counts
and serum IgG levels, were also unaffected. Urinalyses,
electrocardiograms and body temperatures were not affected,
and pathological examination revealed no treatment-related
alterations [472429].
Clinical Development
Phase I
RA
In a pilot study, patients (n = 11) with refractory RA
received MRA in saline (50 or 100 mg iv) administered once
or twice weekly. The treatment was well tolerated and no
major side effects were observed except for the appearance
of anti-idiotypic antibody in one case, resulting in
withdrawal from the trial. A transient decrease in neutrophil
counts, mostly within the normal range, was observed in
most of the cases on the day following MRA administration.
In the eight patients who received MRA treatment for more
than 8 weeks, swollen joints, pain, tenderness and morning
stiffness in the joint was reduced and anemia,
thrombocytosis, hypoalbuminemia and polyclonal hyper-γ-
globulinemia all improved within 2 months in every patient.
At 8 weeks, clinical response was 88%, as assessed by the
American College of Rheumatology 20% response (ACR20)
criteria, and 50%, as assessed by ACR50 criteria. The
therapeutic effects of the treatment were maintained
throughout the 6-month treatment period [475384].
An open-label trial evaluated the safety and efficacy of
repetitive MRA treatment in 15 patients with active RA.
MRA (2, 4 or 8 mg/kg iv) was administered three-times over
a period of 2 h every other week. All patients tolerated MRA
treatment, showed improvement and were allowed to
remain on MRA treatment for 24 weeks. Patients were
further assessed for safety (4 weeks after the last dose) and
efficacy. The treatment was well tolerated at all doses and
no serious adverse events were observed. CRP, serum
amyloid A protein levels and ESR were completely
normalized in 12 out of 15 patients (80%) within 6 weeks.
Hemoglobin and serum albumin levels were normalized in
all patients. In addition, decreases in tender or swollen joint
counts were also noted. Production of antibodies to MRA
was not observed in any patients [475346].
Castleman's disease
MRA (50 or 100 mg) was administered either once or twice
weekly to patients with multicentric plasma-cell-type or
mixed-type Castleman's disease (n = 7). The trough level of
serum MRA was 10 µg/ml during maintenance treatment
using 50 mg of MRA twice weekly, and decreased to 5
µg/ml using a treatment of 100 mg of MRA once weekly.
Treatment was well tolerated except for a transient and mild
decrease in granulocyte counts on the day after MRA
administration in two patients who spontaneously
recovered within 2 days. No decrease in T-cell function was
observed. Fever and fatigue disappeared, and anemia, as
well as serum levels of CRP, fibrinogen and albumin, began
to improve immediately after MRA administration. After 3
months of treatment, hyper-γ-globulinemia and
lymphadenopathy were also remarkably alleviated, as were
renal function abnormalities in patients with amyloidosis.
Autoantibodies such as antinuclear antibody and anti-DNA
antibody disappeared. Histopathological examination of
lymph nodes revealed a reduction in follicular hyperplasia
and vascularity after MRA treatment. These data showed
that MRA could achieve marked responses in the refractory
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form of this disease without significant adverse reactions or
development of neutralizing antibodies [475337], [475384].
Phase II
RA
Registered RA patients (n = 164) were entered into a double-
blind, placebo-controlled trial in which either placebo or MRA
(4 or 8 mg/kg iv) were infused every 4 weeks for 3 months
without the use of disease-modifying antirheumatic drugs.
Patients were permitted to take corticosteroids (10 mg/day or
less) and non-steroidal anti-inflammatory drugs. The average
rates of reduction of joint pain and joint swelling for the
placebo group were 7.7 and 2.6%, respectively, compared
with reductions of 63.1 and 63.4%, respectively, in the 8
mg/kg MRA group. Furthermore, this treatment group
exhibited improvement in inflammatory markers and
increased bone formation markers, as well as a reduction in
bone absorption markers. The ACR20 responses for the
placebo, 4 and 8 mg/kg groups were 11.3, 57.4 and 78.2%,
respectively, and the ACR50 responses of the three groups
were 1.9, 25.9 and 40.0%, respectively [459399], [468323].
In a double-blind, randomized trial, patients (n = 54) with
active RA were allocated to four treatment groups and
received a single dose of MRA (0.1, 1.0, 5.0 or 10.0 mg/kg iv)
or placebo. A significant difference was observed between
the 5.0 mg/kg and placebo group at week 2 (p = 0.011). Five
out of nine patients (55.6%) in the 5.0 mg/kg group and
none in the placebo group demonstrated ACR20 responses.
Baseline disease activity (DAS) ranged from 6.5 to 6.9. At
week 2, the DAS for the 5.0 and 10.0 mg/kg groups was 4.8
and 4.7, respectively. ESR and CRP levels in the 5 and 10
mg/kg groups normalized 1 week after treatment and
remained normal for 3 weeks [475348].
Side Effects and Contraindications
The phase II trial of MRA showed the overall incidences of
adverse events were 72.2, 81.5 and 89.1% (serious events: 3.7,
1.8 and 3.6%) in the placebo, 4 and 8 mg/kg MRA groups,
respectively, and the incidences of infection were 16.7, 22.2
and 20.0%, respectively. Two serious events in the 8 mg/kg
group comprised of one death from a recurrent Epstein-Barr
virus infection and an allergic peritonitis. There was one
secondary infection from burn injuries to the leg in the 4
mg/kg group. In the placebo group, one instance of
traumatic subarachnoid hematoma and one instance of a
femur fracture were reported. Fluctuations in laboratory test
values observed, included significant rises in total
cholesterol levels and triglyceride levels, although the
atherogenic index remained largely unchanged [468323].
Another double-blind, randomized trial showed that the
most common adverse effect reported was diarrhea,
occurring in 17.8% of the patients. One patient died due to
myocardial infarction but this was unlikely to be related to
MRA treatment [475384].
Current Opinion
Anticytokine therapies represent important new advances in
the treatment of RA and other cytokine-related diseases.
Tumor necrosis factor (TNF) antagonists such as infliximab
(Centocor Inc), etanercept (Amgen Inc), adalimumab
(Abbott Laboratories Ltd) and IL-1 antagonists such as
anakinra (Amgen Inc) have been, or are being developed for
this purpose. MRA is capable of specifically inhibiting IL-6
functions, and pharmacological studies suggest that it has
therapeutic potential for the treatment of IL-6-related
diseases, such as RA, CD, SLE, Castleman's disease and MM.
Phase I and II trials have provided strong suggestive
evidence that MRA is effective in the treatment of RA and
Castleman's disease. The therapy is well tolerated with a
transient decrease in neutrophil or granulocyte counts. Like
other anticytokine immunotherapies, infection was also
observed in MRA clinical studies. Thus, caution and close
monitoring for this adverse event are necessary in later
clinical trials. Furthermore, skepticism exists that IL-6 is as
important as IL-1 and TNF in the pathogenesis of these
autoimmune and inflammatory diseases, and it is, therefore,
worthwhile comparing the effects of MRA with IL-1 or TNF
antagonists, and the effects in combination with IL-1 or TNF
antagonists. If it is established that MRA is as effective as IL-
1 or TNF antagonists, or that MRA can augment the effect of
IL-1 or TNF antagonists, it may capture a substantial portion
of the considerable market for anticytokine therapies.
Commercial Opinion
In August 1999, Lehman Brothers gave MRA a 10% probability
of reaching the market with an expected launch in 2003. Sales
were predicted to peak in 2010 at US $75 million [349228].
Development history
Phase II studies in RA were underway in Japan and Europe by September [422477] and November 2001 [434336],
respectively; by May 2002, phase II trials for RA in Japan had been completed [459399], [466916], [469932]. By November
2002, phase II trials in Japan for Castleman's disease had been completed [469932], and phase I trials for this indication were
ongoing in the US by October 2002. By this time, phase II trials in juvenile idiopathic arthritis were ongoing in Japan and the
UK, and phase II trials had been initiated in Japan for CD. Also by October 2002, MRA was in phase II trials in France and
phase I trials in the UK for the treatment of MM [466457], [466916]. By November 2002, a phase I trial for SLE had been
initiated in the US [469932]. In May 2001, Chugai predicted launch in 2005/2006 [409785]. By October 2002, Chugai
anticipated moving the drug candidate into phase III studies as quickly as possible [466737].
As part of the merger agreement between Chugai and Roche in December 2001, Roche gained opt-in rights on MRA in the
US [434295]. In October 2002, Chugai reported that it would closely cooperate with Roche for joint development, production
and marketing on a worldwide basis, except in Japan and South Korea [466737]. In November 2000, MRA was granted
orphan drug status in Japan for the target indication of Castleman's disease [391361]. In May 2000, Chugai signed multiple
patent license agreements with Protein Design Laboratories whereby Chugai was to receive non-exclusive worldwide
licenses under PDL's antibody humanization patents for an undisclosed number of Chugai antibody targets. Chugai was to
pay PDL upfront signing and licensing fees totalling US $6.04 million [366951]. In July 1996, Chugai filed patent application
WO-09620728 for the use of IL-6 receptor mAbs to increase the sensitivity of tumor cells to antitumor agents.
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Developer Country Status Indication Date Reference
Chugai Pharmaceutical Co Ltd France Phase II Myeloproliferative disorder 11-OCT-02 466457
Chugai Pharmaceutical Co Ltd Japan Phase II Arthritis 11-OCT-02 466457
Chugai Pharmaceutical Co Ltd Japan Phase II Castleman's disease 20-MAY-02 457278
Chugai Pharmaceutical Co Ltd Japan Phase II Crohn's disease 12-MAR-01 400514
Chugai Pharmaceutical Co Ltd Japan Phase II Rheumatoid arthritis 19-NOV-99 347955
Chugai Pharmaceutical Co Ltd UK Phase II Arthritis 11-OCT-02 466457
Chugai Pharmaceutical Co Ltd Western Europe Phase II Rheumatoid arthritis 12-NOV-01 434336
Chugai Pharmaceutical Co Ltd UK Phase I Myeloproliferative disorder 11-OCT-02 466457
Chugai Pharmaceutical Co Ltd US Phase I Castleman's disease 11-OCT-02 466457
Chugai Pharmaceutical Co Ltd US Phase I Systemic lupus
erythematosus
13-NOV-02 469932
Literature classifications
Key references relating to the technology are classified according to a set of standard headings to provide a quick guide to
the bibliography. These are as follows:
Chemistry: References which discuss synthesis and structure-activity relationships.
Biology: References which disclose aspects of the drug's pharmacology in animals.
Metabolism: References which discuss metabolism, pharmacokinetics and toxicity.
Clinical: Reports of clinical phase studies in volunteers providing, where available, data on the following: whether the
experiment is placebo-controlled or double- or single-blind; number of patients; dosage.
Chemistry
Study Type Result Reference
Synthesis
and SAR.
MRA was constructed by grafting the complementarity-determining regions from mouse PM-1, a specific
monoclonal antibody against human IL-6R, into human IgG to recreate a functional antigen-binding site in
a reshaped human antibody.
154800
Biology
Study Type Effect Studied Experimental Model Result Reference
In vivo Anti-inflammatory
effects.
Collagen-induced
arthritis in the
cynomolgus monkey.
MRA (10 mg/kg iv) administered once weekly for 13
weeks inhibited arthritis symptoms, CRP level and
ESR. Joint destruction was suppressed.
472418
In vivo Anti-inflammatory
effects.
SCID mice xenograft
with human RA synovial
tissue.
MRA (100 µg ip) administered once weekly for 4
weeks decreased the number of inflammatory cells
in the implanted tissues.
475344
In vivo Anti-inflammatory
effects.
Murine colitis model
induced by transfer with
CD45Rbhigh CD4+ T-
cells from BALB/c mice.
Rat anti-murine IL-6R antibody administered by ip
injection (2 mg at the time of colitis induction and 1
mg weekly up to 8 weeks) significantly inhibited the
average colitis score and T-cell expansion.
475336
In vivo Antimyeloma activity. SCID mice xenograft
MM model induced by iv
injection of the human
MM cell line, KPMM2.
A single iv injection of MRA (2 mg) on the day after
tumor transplantation suppressed the elevation of
serum M-protein and development of the tumor-
associated abnormalities, and significantly increased
lifespan.
475345
In vivo Immunosuppressive
ability.
BWF1 mice as a model
of human SLE.
Administration of rat anti-mouse IL-6R antibody
suppressed the development of the autoimmune
disease.
475341
Metabolism
Study Type Effect Studied Model Used Result Reference
In vivo Kinetic properties. Normal cynomolgus monkeys to
which MRA was administered (4
or 40 mg/kg iv) once weekly for
13 weeks.
Serum concentrations of MRA showed
linearity between the two doses.
472429
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Clinical
Effect Studied Model Used Result Reference
Safety and efficacy in RA
patients.
In a phase I open-label trial, MRA (2, 4 or 8
mg/kg) was administered three times by iv
infusion over a period of 2 h every other
week in patients (n = 15) with RA.
The treatment was well tolerated at all doses
without any serious adverse events. CRP
levels, ESR and clinical symptoms were
decreased or normalized.
475346
Safety and efficacy in RA
patients.
In a phase II double-blind, placebo-
controlled trial, either placebo or MRA (4 or
8 mg/kg) were infused iv every 4 weeks for
3 months to RA patients (n = 164).
The ACR20 responses of the placebo, 4 and
8 mg/kg groups were 11.3, 57.4 and 78.2%,
respectively. Overall incidences of adverse
events were 72.2, 81.5 and 89.1% (serious
events were 3.7, 1.8 and 3.6%), respectively,
in the three groups.
468323
Safety and efficacy in RA
patients.
In a phase I double-blind, randomized trial,
a single iv dose of placebo or MRA (0.1,
1.0, 5.0 or 10.0 mg/kg) was administered to
RA patients (n = 45).
Five of nine (55.6%) patients in the 5.0
mg/kg group and none in the placebo group
demonstrated ACR20 responses. ESR and
CRP levels in the 5 and 10 mg/kg groups
normalized. The most common adverse
effect reported was diarrhea, occurring in
17.8% of the patients.
475384
Safety and clinical
response in RA patients.
In a phase I pilot study of refractory RA,
patients (n = 11) received 50 or 100 mg
MRA iv in saline once or twice weekly.
The treatment was well tolerated and no
major side effects were observed. There was
improvement in the level of swollen joints,
pain, tenderness and morning stiffness in the
joints, anemia, thrombocytosis,
hypoalbuminemia, and polyclonal hyper-γ-
globulinemia. Clinical response was 88% as
assessed by ACR20 criteria at 8 weeks.
475384
Safety and efficacy in
Castleman's disease
patients.
A phase I trial in which MRA (50 or 100 mg)
was administered either once or twice
weekly to treat Castelman's disease
patients (n = 7).
Treatment was well tolerated except for a
transient and mild decrease in granulocyte
counts. Fever and fatigue disappeared, and
laboratory index improved.
475337
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